
Bulletin from the Extraordinary General Meeting of Hansa Medical AB (publ)

The Extraordinary General Meeting of Hansa Medical unanimously followed the proposal from the board of Hansa Medical and resolved to carry out a directed share issue to NXT2B, the privately owned venture capital firm of Bengt Ågerup. In addition, the Extraordinary General Meeting resolved to carry out a fully guaranteed share issue with preferential rights. Hansa Medical raises in total SEK 46 million. The investment will make it possible to carry out clinical phase 1 and phase 2 trials with IdeS, the most important and advanced drug candidate in the Hansa Medical portfolio.

Resolution regarding directed share issue to NXT2B

The Extraordinary General Meeting resolved that the company's share capital shall increase by a maximum of SEK 25,000,005 through a share issue of a maximum of 5,000,001 shares without preferential rights for the shareholders primarily under the following terms. With the ambition to broaden the investor base, the Swedish corporation Nexttobe AB (NXT2B) shall have the right to subscribe for the shares in place of the shareholders. The price shall be SEK 5.50 per share. Bengt Ågerup or any juridical person owned by Bengt Ågerup at 100%, shall have the right to subscribe for the shares not being subscribed for by Nexttobe AB. The shares shall be subscribed for through payment on January 11, 2012. New shares shall entitle to dividends on the first record day for dividends taking place after the new shares have been registered.

Resolution regarding share issue with preferential rights

The Extraordinary General Meeting resolved that the company's share capital shall increase by a maximum of SEK 18,521,145 through a share issue of a maximum of 3,704,229 shares, with preferential right given to shareholders according, primarily, to the following conditions. One owned share on the record day, 29 February 2012, gives the right to one subscription right. Five subscription rights give the right to the subscription of one new share at the subscription price of SEK 5 per share. Shares which are not distributed according to preferential right shall be distributed between individuals subscribing for shares without preferential right, whereby distribution will be carried out, in the first instance, to individuals subscribing for shares with support of preferential right proportional to the number of subscribed shares, and, in the second instance, to others subscribing for shares without preferential right proportional to the number of subscribed shares. The subscription period will be 5 March until 19 March 2012. The Board of Directors shall have the right to extend the subscription period. Subscription for shares with the support of preferential rights shall take place through payment. Subscription for shares without the support of preferential rights shall take place through the subscription list, whereby payment must be made within three working days from notification of distribution. New shares shall entitle to dividends on the first record day for dividends taking place after the new shares have been registered.

A complete proposal for the resolutions, accounting documents, the auditor's report and complete supporting documentation for the resolutions in general is available from the company and on the company's website. These documents will be sent on request to any shareholder providing a postal address.

For further information, please contact:

Emanuel Björne, CEO Hansa Medical AB

Mobile: +46 707 17 54 77

E-mail: emanuel.bjorne@hansamedical.com

ABOUT HANSA MEDICAL

Hansa Medical is a biotechnology research and development company focused on the treatment and diagnosis of inflammatory diseases. The company develops innovative biological pharmaceuticals and diagnostic methods both independently and in partnership with large, established companies. At present, the company is primarily undertaking three development projects: IdeS, EndoS and HMD-301. New development projects and product candidates generated through cooperation with medical academic research are continuously evaluated. Hansa Medical is listed on NASDAQ OMX First North, and Remium Nordic AB is the company's Certified Adviser.

Hansa Medical AB
P.O. Box 785
SE-220 07 Lund
Telephone +46 46 16 56 70
Fax +46 46 12 77 75
info@hansamedical.com
www.hansamedical.com

VISITING ADDRESS:
Scheelevägen 22
Lund